flow trial semaglutide kidney outcomes nejm 2024 hazard ratio Patients with type 2 #diabetes and chronic disease are at high risk for kidney failure, cardiovascular events, and death. Whether treatment with would mitigate these risks is unknown. Research Summaries accompanying Original Articles
Description
In July 2024, a retrospective study on overweight or obese adults treated for type 2 diabetes, 81.8% of people receiving tirzepatide (Mounjaro) lost at least 5% of their weight within one year compared to 66.5% of those using semaglutide (Ozempic), a significant difference (which means it did not just happen by chance)
When combined with clinical assessment and injection technique optimization, genetic context may help anticipate tolerability and optimize your treatment plan
They will also help assess whether you are likely to be covered by the Medicare GLP-1 Bridge program
doi: 10.1136/bmjopen-2018-023458 [DOI] [PMC free article] [PubMed] [Google Scholar] 129.Anson M, Zhao SS, Austin P, Ibarburu GH, Malik RA, Alam U
Pyruvate carboxylase catalyzes the ATP-dependent incorporation of bicarbonate into pyruvate, producing oxaloacetate
In addition, the knowledge score was affected significantly by the presence of chronic diseases and increased BMI
